Literature DB >> 19801576

PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation.

Hongyu Gao1, Yan Wang, Tomasz Wegierski, Kassiani Skouloudaki, Michael Pütz, Xiao Fu, Christina Engel, Christopher Boehlke, Hongquan Peng, E Wolfgang Kuehn, Emily Kim, Albrecht Kramer-Zucker, Gerd Walz.   

Abstract

Autosomal dominant polycystic liver disease (PCLD) is caused by mutations of either PRKCSH or Sec63, two proteins associated with the endoplasmic reticulum (ER). Both proteins are involved in carbohydrate processing, folding and translocation of newly synthesized glycoproteins. It is postulated that defective quality control of proteins initiates endoplasmic reticulum-associated degradation (ERAD), which disrupts hepatic homeostasis in patients with PRKCSH or Sec63 mutations. However, the precise molecular mechanisms are not known. Here, we show that over-expression or depletion of PRKCSH in zebrafish embryos leads to pronephric cysts, abnormal body curvature and situs inversus. Identical phenotypic changes are induced by depletion or over-expression of TRPP2. Increased PRKCSH levels ameliorate developmental abnormalities caused by over-expressed TRPP2, whereas excess TRPP2 can compensate the loss PRKCSH, indicating that the proteins share a common signaling pathway. PRKCSH binds the C-terminal domain of TRPP2, and both proteins co-localize within the ER. Furthermore, PRKCSH interacts with Herp, and inhibits Herp-mediated ubiquitination of TRPP2. Our findings suggest that PRKCSH functions as a chaperone-like molecule, which prevents ERAD of TRPP2. Dysequilibrium between TRPP2 and PRKCSH may lead to cyst formation in PCLD patients with PRKCSH mutations, and thereby account for the overlapping manifestations observed in PCLD and autosomal dominant polycystic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19801576     DOI: 10.1093/hmg/ddp463

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Herp regulates Hrd1-mediated ubiquitylation in a ubiquitin-like domain-dependent manner.

Authors:  Melanie Kny; Sybille Standera; Rasmus Hartmann-Petersen; Peter-Michael Kloetzel; Michael Seeger
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

Review 4.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

5.  Polycystin-1 negatively regulates Polycystin-2 expression via the aggresome/autophagosome pathway.

Authors:  Valeriu Cebotaru; Liudmila Cebotaru; Hyunho Kim; Marco Chiaravalli; Alessandra Boletta; Feng Qian; William B Guggino
Journal:  J Biol Chem       Date:  2014-01-23       Impact factor: 5.157

Review 6.  Isolated polycystic liver disease.

Authors:  Qi Qian
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

7.  A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.

Authors:  Sorin V Fedeles; Xin Tian; Anna-Rachel Gallagher; Michihiro Mitobe; Saori Nishio; Seung Hun Lee; Yiqiang Cai; Lin Geng; Craig M Crews; Stefan Somlo
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

8.  HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Authors:  Sergio A Gradilone; Stefan Habringer; Tatyana V Masyuk; Brynn N Howard; Anatoliy I Masyuk; Nicholas F Larusso
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

Review 9.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

10.  Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

Authors:  E Waanders; H Venselaar; R H M te Morsche; D B de Koning; P S Kamath; V E Torres; S Somlo; J P H Drenth
Journal:  Clin Genet       Date:  2010-01-20       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.